Gut-derived bacterial extracellular vesicles: the microbial dark matter contributing to host inflammation and cardiometabolic disease Authors: Blayne Oliver, Michael Sun, Young Seo Lee, Ssanggoo Cho, Tianyi Zhu, David Durgan, Gary Sweeney Published: 2026 ABSTRACT ABSTRACTCardiometabolic diseases (CMDs) represent a growing global health burden, with chronic inflammation and gut microbiota dysbiosis emerging as central contributors to their pathogenesis. Among the diverse microbial products influencing host physiology, bacterial extracellular vesicles (BEVs) have gained attention as potent mediators of interkingdom communication. These nanoscale vesicles, secreted by both gram-positive and gram-negative bacteria, carry a complex cargo of proteins, lipids, nucleic acids, and pathogen-associated molecular patterns (PAMPs) that interact with host pattern recognition receptors (PRRs) to modulate immune and metabolic responses. BEVs can traverse intestinal barriers, disseminate systemically, and accumulate in cardiometabolic tissues, where they influence inflammation, insulin sensitivity, and organ function. This review synthesizes current evidence linking BEVs to CMDs, explores mechanisms of BEV-host crosstalk, and highlights their potential as diagnostic biomarkers and therapeutic vectors. We also discuss emerging technologies for BEV characterization and propose future research directions to better understand their role in CMD pathophysiology. Introduction Cardiometabolic diseases (CMDs) are a diverse group of interrelated disorders including metabolic diseases like obesity, diabetes, and liver disease (MASH and NAFLD), along with cardiovascular complications such as heart disease, heart failure, and related conditions like atherosclerosis and hypertension. Although advances in prevention and treatment have been made over the last several decades, the global health burden of CMDs continues to grow. 1-4 For example, the global rate of obesity, a key risk factor for CMD, has more than tripled since 1980 5 resulting in more than one-third of the population being classified as overweight or obese. 6 While CMDs are shaped by a complex interplay of genetics, diet, and lifestyle, they share common risk factors and underlying pathophysiology, including chronic low-grade inflammation. 7 , 8 In recent years, the “gut microbiota revolution” has revealed the intestinal microbiota as a central regulator of metabolic and immune homeostasis. 9 Perturbations to the composition and function of these communities, termed dysbiosis, have been consistently linked to cardiometabolic pathology including obesity, T2D, CVD, and NAFLD/MASH. Mechanistic studies have largely focused on the roles of soluble pathogen-associated molecular patterns (PAMPs) and microbial metabolites like short-chain fatty acids, secondary bile acids, and trimethylamine N-oxide (TMAO) and their influence on host cardiometabolic function. However, emerging evidence is revealing an underappreciated role of gut-derived bacterial extracellular vesicles (BEVs) as important modulators of host cardiometabolic function. BEVs are nanoscale, membrane-bound particles released by both pathogenic and beneficial microbes that serve as potent mediators of bacteria‒host communication. BEVs carry diverse cargo including various PAMPs, which can interact with host pattern recognition receptors (PRRs) to modulate immune and metabolic pathways. 10 , 11 Importantly, BEVs can traverse the intestinal barrier, enter systemic circulation, and accumulate in metabolic organs, where they may contribute to local inflammation and metabolic dysfunction. 12-17 The goal of this review is to synthesize current knowledge on how gut-derived BEVs influence CMD pathogenesis, with a focus on their cargo composition, mechanisms of host interaction, systemic dissemination, and direct evidence linking them to CMD pathology. We also discuss their potential as diagnostic biomarkers and therapeutic delivery vehicles, and highlight key knowledge gaps and emerging tools that can advance the field. Brief overview of bacterial extracellular vesicles (BEVs) Extracellular vesicles (EVs) are increasingly recognized as essential mediators of interkingdom communication. They are secreted by cells from all domains of life, including bacteria, to regulate processes in both local and distant cells. 18 Bacterial EVs (BEVs) are nano-sized compartments measuring 20–400 nm in diameter that are naturally generated by the budding off of bacterial membranes. BEVs have been extensively studied in gram-negative bacteria since they were discovered in the 1960s 19 and are known to result from several biogenesis mechanisms resulting in distinct subtypes including outer membrane vesicles (OMVs), outer-inner membrane vesicles (OIMVs), and explosive OMVs (EOMVs) 20 (Figure 1). Numerous gram-positive bacteria have also been shown to produce BEVs containing the cytoplasmic membrane (CMVs) despite their thick cell wall 21 (Figure 1). BEV production and composition. BEVs are nanoscale membrane compartments produced by both gram-positive and gram-negative bacteria. They result from several biogenesis mechanisms leading to a diverse composition of membrane components and molecular cargo. Outer-membrane vesicles (OMVs in gram-negative bacteria) contain outer-membrane-associated proteins, lipids, and sugars. Outer-inner membrane vesicles (OIMVs) contain both membrane and cytoplasmic content, leading to the packaging of nucleic acids, enzymes, toxins in addition to membrane components. Explosive outer membrane vesicles (EOMVs) can contain both membrane and cytoplasmic components; however, these vesicles are produced by explosive cell lysis and recircularization, so their cargo may differ from OIMVs as they are produced during cell death. Gram-positive cytoplasmic-membrane vesicles (CMVs) can also contain both membrane and cytoplasmic molecules. Additionally, these vesicles are known to carry gram-positive-specific components like lipoteichoic acid (LTA). Given the broad evolutionary conservation of EVs and the complexity of cargo they carry, it is evident that these vesicles play an important role in facilitating both bacteria–bacteria and bacteria–host communication. The significance of BEVs stems from their capacity to transfer information to other cells, thus influencing their function. This “information” is communicated through the diverse set of biomolecules that are packaged within the BEV and embedded in the membrane, commonly referred to as cargo. Indeed, bacteria can package cargo into BEVs from all major classes of biomolecules including genetic components, proteins, lipids, sugars, and even metabolites. While the mechanisms for packaging cargo into BEVs remain largely unknown, they seem to depend on several factors such as the identity of the parent bacteria, environmental factors, and the biogenesis mechanism. 22 For instance, due to the lack of inner-membrane in OMVs from gram-negative bacteria, these BEVs tend to be enriched with outer membrane proteins and lipids compared to other BEV types. 23 On the other hand, the addition of bacterial cytoplasmic contents in OIMVs, EOMVs, and CMVs results in the presence of genetic components (e.g. DNA, mRNA, sRNA, and siRNA), cytoplasmic proteins, and virulence factors. 24 Evidence suggests that the loading of BEV cargo is not passive, but instead cargo is selectively loaded into BEVs. 25-27 Additionally, a strain of bacteria can release BEVs with different cargo depending on environmental conditions (e.g. heat, pH, metabolic stress). 27 , 28 Ultimately, BEVs provide a vehicle that facilitates both bacteria–bacteria and bacteria–host communication. For example, they are known to help bacterial communities coordinate social group activities based on environmental cues or stressors, a process known as quorum sensing. 23 These group activities, mediated by BEVs, generally benefit bacterial communities by providing protection from antibiotics or phage infections through the formation of biofilms. 29 BEVs can also contribute to nutrient exchange 23 and horizontal gene transfer, 30 , 31 allowing bacterial communities to rapidly adapt to changing environments. Finally, the functional consequence of BEVs that is most relevant to this review is their ability to modulate host cell function through the delivery of cargo. In this review, we will outline the interactions between BEVs and host cells and discuss the impacts on physiology of host cardiovascular and metabolic systems. In summary, BEVs are a diverse group of nanoparticles produced by bacteria through various biogenesis pathways. Far from being mere byproducts of bacterial metabolism, BEVs represent an evolutionarily conserved strategy for transferring complex molecular information between cells, whether within microbial communities or across kingdoms to host tissues. Depending on their cargo composition and environmental context, BEVs can influence host biology in ways that are beneficial, neutral, or detrimental to both bacteria and host. This dual-potential underlies their significance as mediators of microbe–host interactions and sets the stage for exploring their roles in the pathophysiology of cardiometabolic diseases. Furthermore, we propose that BEVs constitute a highly druggable class of nanoscale particles with value as both actionable therapeutic targets and as intrinsically biocompatible nanocarriers for precision drug delivery. The gut microbiota in cardiometabolic disease When considering the consequences of BEV-host cell interactions, one should first look at the microbiota–intestinal interface. The human intestine houses the largest and most diverse community of bacteria in the body, known as the gut microbiota. Conservative estimates suggest that the total number of bacteria in the average human is nearly forty trillion (4 × 1013), outnumbering the total number of human cells in the body. 32 Ninety-five percent of these bacteria reside within the intestinal tract, primarily in the colon. 33 Collectively, the gut microbiota participate in a symbiotic relationship with their human host, a bond that has developed through millennia of coevolution. 34 These commensal microorganisms perform many crucial functions such as aiding in host nutrient digestion and absorption, synthesis of essential vitamins, pathogen resistance, and training the immune system to distinguish friend from foe. 35 , 36 However, various factors including diet, lifestyle choices, and antibiotic use may disrupt the compositional balance of the gut microbiota. This imbalance, known as “dysbiosis,” can lead to chronic inflammation and give rise to many complications linked to cardiometabolic diseases. Recently, the gut microbiota has gained serious attention in the field of cardiometabolic disease due to increasing associations in both human and animal studies (discussed below). Among the various bacteria present in the gut, the two predominant phyla are Firmicutes and Bacteroidetes, which differ in their general metabolic capacities. 37 , 38 A commonly used metric of gut microbiota composition is the ratio of Firmicutes-to-Bacteroidetes, or F/B ratio. A greater F/B ratio, or increased abundance of Firmicutes, was initially associated with disease-related dysbiosis due to early studies showing this relationship in the context of obesity. 39 However, a decreased F/B ratio has also been observed in various diseases, including type 2 diabetes and nonalcoholic fatty liver disease. 40 , 41 A more modern perspective is that the F/B ratio is a general measure of gut microbiota composition, and that any shift can be indicative of disease-associated dysbiosis. Another important metric in microbiota research is diversity, or the number of different taxa within a sample. This measure of microbiota composition tends to be more consistent across different disease settings with increased gut microbiota diversity associated with health and reduced diversity associated with disease. The following subsections will discuss the gut microbiota dysbiosis observed in various cardiometabolic diseases and studies that suggest a causal role for microbiota in cardiometabolic diseases. Obesity Obesity, deemed a modern epidemic in Westernized societies, is a major health concern and common risk factor for many other diseases, particularly cardiometabolic diseases. 6 , 42 The gut microbiota can induce obesity through a variety of mechanisms including altered energy absorption, central appetite, fat storage, and chronic inflammation (summarized by Liu, 2021 and Mitev, 2019). 43 , 44 Gut microbiota dysbiosis is well established in obesity with reduced bacterial diversity, increased F/B ratio, and increased inflammation all commonly reported in both mice and humans with obesity. 45-49 Low bacterial diversity is linked to more overall adiposity, insulin resistance, dyslipidemia, and a more pronounced inflammatory phenotype, all complications found in obesity. 46 , 47 Furthermore, low bacterial diversity can be used as a predictor for increased weight gain in people with obesity. 46 , 47 Short-chain fatty acids (SCFAs) have repeatedly been identified as a microbial product that differs in obesity; however, there are discrepancies in the associations found. A meta-analysis of seven studies (total n = 444) found that SCFAs were increased in individuals with obesity. 50 Whereas a more recent large observational study spanning 5 countries (n = 1904) found that obesity was significantly associated with a reduction in fecal SCFAs. 51 More work is needed to elucidate the role of SCFAs in obesity phenotypes. While the associations between gut microbiota composition and obesity are evident, a growing number of fecal microbiota transplant (FMT) studies have helped to establish a causal role for the gut microbiota in obesity. In a transformative study by Turnbaugh et al. in 2006, gut microbiota from obese or lean donor mice were transferred to germ-free recipients. They found that recipient mice colonized with obese gut microbiota gained more body fat compared to recipients colonized with microbiota from lean mice, despite both groups having equivalent calorie intake. 39 This effect was attributed to a greater capacity to harvest energy from the diet in obese gut microbiota. Likewise, FMT from lean mice to diet-induced obese mice led to the improvement of metabolic markers in recipients. 52 Importantly, this phenomenon is not limited to the gut microbiota of mice. In a human-to-mouse FMT study, Ridaura et al. isolated fecal microbiota from four pairs of twins, discordant for obesity, and transferred them to germ-free mice. Again, recipients of obese gut microbiota gained more weight and adiposity compared to recipients of lean microbiota, despite equal food consumption. 53 This study effectively dissected the contributions of gut microbiota and host genetics to reveal a significant independent effect of the gut microbiota in obesity. Although the influence of FMTs on obesity are consistent in mouse recipients, human randomized clinical trials (RCT) have been inconclusive thus far. The FMT-TRIM trial in adults with obesity found that FMT from lean donors had no improvement in insulin sensitivity or body composition within 12 weeks compared to placebo controls. 54 However, a 4-year follow-up of the Gut Bugs Trial in adolescence with obesity found that FMT from lean donors led to reduced waist circumference, total body fat, metabolic severity score, and inflammation compared to placebo controls. 55 These discrepancies may be due to donor variability or differences between the cohorts including age, sex, sample size, or time to follow-up (FMT-TRIM consisted of adults, 71% female, n = 12/group; whereas the Gut Bugs Trial consisted of adolescents, 50% female, n = 27/group). Nonetheless, these RCTs highlight the need to move beyond rodent models to gain a better understanding of the mechanisms by which the gut microbiota contribute to obesity in humans. In this vein, studies have begun to identify individual microbes that can modulate features of obesity in humans. For instance, the abundance of the commensal family Christensenellaceae is inversely correlated with BMI. 56 Additionally, supplementation with the common probiotic Akkermansia muciniphila improved metabolic markers in overweight and obese individuals. 57 Although limited, these studies highlight the potential to translate findings from gut microbiota to treatment approaches for obesity. Type-2 diabetes (T2D) and insulin resistance Type 2 diabetes (T2D) is a progressive metabolic disorder characterized by pancreatic β-cell dysfunction and insulin resistance, leading to elevated blood glucose levels. 58 It affects more than 400 million people globally and accounts for 95% of all diabetes cases. 59 , 60 T2D is consistently linked to moderate gut microbiota dysbiosis, but unlike in obesity, there is a discrepancy in the reported microbiota compositional changes at the phylum level. 40 , 61 Looking for associations beyond the phylum level, several studies have reported that T2D is associated with gut microbiota alterations involving a decrease in SCFA-producing bacteria and an increase in opportunistic pathogens. 62–67 Additionally, the abundance of Akkermansia muciniphila was shown to negatively correlate with HbA1c, a diabetes biomarker, and is commonly found to be diminished in T2D patients. 65 , 67 However, mechanisms underlying the beneficial effects of A. muciniphila are still unknown. In an RCT with 58 overweight or obese T2D participants, supplementation with A. muciniphila reduced body weight, fat mass, and HbA1c compared to placebo controls. 68 However, this effect only occurred in participants with low baseline levels of A. muciniphila in the gut. 68 Interestingly, a decrease in A. muciniphila was identified in both pre- and post-onset of T2D, suggesting a potential role in disease progression. 69 While results from animal studies suggest that A. muciniphila appears to be effective at reducing the onset of T2D, 68 more human studies are needed to elucidate mechanistic links and reveal what patients will benefit most from this therapeutic approach. In addition to A. muciniphila, other bacterial taxa such as Bacteroides 70 and Lactobaccillus 71 , 72 have shown similar beneficial trends in animal models and people with T2D. Again, a causal relationship between the gut microbiota and T2D has been established through FMT studies. In a genetic mouse model of spontaneous diabetes (db/db model), investigators reported an altered gut microbiota composition, and FMT of these microbes induced gut microbiota changes and a diabetes-like metabolic phenotype in WT (microbiota-depleted) recipients. 73 In humans, FMT from lean donors showed therapeutic benefit in patients with metabolic syndrome, a condition closely linked to T2D, by increasing their insulin sensitivity. 74 These studies emphasize the importance of exploring the underlying molecular mechanisms to explain how specific bacteria participate in the development of T2D and if gut microbiota can be used as an effective target for T2D therapies. Cardiovascular disease Several studies have suggested that gut microbiota dysbiosis can also contribute to the development of cardiovascular diseases including atherosclerosis, 75-79 hypertension, 80-93 stroke, 94-98 ischemic heart disease, 99 , 100 and heart failure. 101 , 102 Atherosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and immune cells in arteries, called plaques. 103 Patients with atherosclerosis have an altered gut microbiota composition with increased abundance of Collinsella, Enterobacteriaceae, and Streptococcus spp, along with functional changes including increased fatty acid degradation, decreased butyrate synthesis, and enrichment of TMA synthesis, a precursor for TMAO. 75 , 78 In mice, atherosclerosis susceptibility was transferred to recipients through the fecal gut microbiota and more interestingly, FMT from an atherosclerosis-resistant strain (NZW/LacJ) tended to be protective in otherwise atherosclerosis-prone recipients (C57BL/6J). 77 Hypertension is another cardiovascular disease that has been strongly linked to the gut microbiota. 104-106 Animal models of hypertension have repeatedly identified a decreased bacterial diversity and increased F/B ratio in hypertension. 80 , 81 Additionally, a decrease in SCFA-producing bacteria are also commonly observed in hypertension. 80 , 85 , 107-109 The causal role of an altered gut microbiota in hypertension has been demonstrated repeatedly by transplanting the gut microbiota from hypertensive animal models and patients to normotensive recipients, which results in elevated BP. 81 , 84 , 86 , 88 , 110 Finally, the gut microbiota has been linked to myocarditis, or inflammation in the heart tissue, which can lead to cardiovascular complications like heart failure and stroke. FMT has been shown to alleviate myocardial damage and improve cardiac function in experimental myocarditis by reducing inflammatory cell infiltration in heart tissue. 111 , 112 Likewise, supplementation with the SCFA butyrate had similar cardiac benefits in these models of myocarditis highlighting the importance of this microbial metabolite. 111 While the gut microbiota has been shown to play an important role in the development of a variety of cardiovascular diseases, the mechanisms underlying these relationships are not fully understood. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) Cardiometabolic diseases affecting the liver have also been linked to gut microbiota dysbiosis. Both adults and children with nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) possess a gut microbiota with significantly lower diversity than healthy controls 41 , 113-116 and the gut microbiota composition correlates with liver biochemistry markers of disease. 41 In fact, one study found the gut microbiota of pediatric patients with NAFLD and NASH to be even less diverse than obese patients. 114 The microbiota compositional changes in patients with liver disease are associated with a lower abundance of SCFA producers along with an increase in proinflammatory bacteria like Collinsella. 41 , 117 What is the connection between altered gut microbiota compositions and cardiometabolic disease? As we have seen, the gut microbiota is implicated across the spectrum of cardiometabolic diseases affecting a range of host tissues including the adipose, pancreas, kidneys, heart, vasculature, and liver. Common to the etiology of each of these diseases is the role of chronic inflammation. Intriguingly, the gut microbiota has been shown to play a crucial role in development and shaping of the host immune system. Chronic inflammation is a major underlying factor that is common across the spectrum of cardiometabolic diseases. 8 , 118-120 Several human studies have found that the altered gut microbiota composition in patients with cardiometabolic diseases is also associated with systemic inflammation including elevated white blood cell counts and serum markers like CRP and IL-1b. 46 , 47 , 121-123 This evidence suggests that the gut microbiota plays a role by initiating or propagating the inflammation that contributes to cardiometabolic diseases. In the remainder of this review, we will explore the idea that BEVs play an important role in mediating gut microbiota-host signaling involved in cardiometabolic diseases by examining the proinflammatory cargo of BEVs. Mechanisms of BEV-host communication in cardiometabolic disease Throughout human history, we have coevolved a symbiotic relationship with the diverse communities of microbiota in our gut. Serving as “host,” the human intestinal tract offers an ideal environment for microbiota by providing protection from external dangers like UV radiation along with ample nutrients from the undigested foods we eat. On the other hand, our gut microbes provide us essential vitamins and nutrients and aid with nutrient absorption and educating our immune system. To ensure the balance of this mutualistic relationship, bacteria and their hosts have developed a language to communicate with each other. This language consists of microbial-associated molecular patterns (MAMPs), often referred to as pathogen-associated molecular patterns (PAMPs) in the context of inflammation, and host pattern recognition receptors (PRRs). Although the direct mechanistic links between BEVs and cardiometabolic diseases are largely unknown, they likely involve the interaction between bacterial PAMPs and host PRRs. BEV cargo delivery Before diving into the specific PAMP–PRR interactions between BEVs and host cells, it is important to understand the general context in which microbial messages are delivered by BEVs to host cells. Initial interactions of BEVs with host cells can occur through three main mechanisms: 1) transient docking by interaction of BEV membrane ligands with surface receptors on host cells, 2) internalization of BEVs into endosomal compartments, or 3) direct fusion of BEV membrane with host cell membrane. 124 These mechanisms are not mutually exclusive and the interaction of BEV membrane ligands with host surface receptors is likely to facilitate both internalization, via receptor-mediated endocytosis, as well as membrane fusion mechanisms. This leads to the direct delivery of internal BEV cargo to the host cell cytoplasm. 125 The interaction of BEVs with innate immune cells like macrophages and dendritic cells is likely to result in internalization by phagocytosis. However, nonphagocytic cells have also been suggested to internalize BEVs through various mechanisms including macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated endocytosis, lipid raft-mediated endocytosis, 124 , 126 and direct membrane fusion. 124-127 While host mechanisms are in place to degrade and remove foreign matter in endosomal compartments, BEVs can protect their cargo from enzymatic degradation and facilitate delivery of cargo into the host cytosol leading to inflammation and metabolic dysfunction. Now that we have a general context by which BEV cargo is delivered to host cells, next we will explore the specific host PRRs that are responsible for sensing known BEV cargoes and outline the links to cardiometabolic diseases. Interactions that mediate BEV-host crosstalk in cardiometabolic diseases Extensive reviews of host PRRs, their ligands, signaling pathways, and resulting changes in cellular function can be found elsewhere. 128-130 In short, PRRs are widely expressed by immune cells and nonimmune cells, including endothelial cells, fibroblasts, and epithelial cells and they work to recognize both extracellular and intracellular pathogens. Several classes of PRRs (TLRs, CLRs, NLRs, RLRs) have been identified to sense all major classes of microbial products including proteins, lipids, carbohydrates, nucleic acids, metabolites, and toxins. The signaling pathways activated by the vast majority of PRRs converge on induction of the master transcriptional regulator, NFκB, or formation of the inflammasome, both of which result in proinflammatory cytokine and chemokine production. 128 Here, we will discuss the host PRRs that are likely to mediate the crosstalk between BEVs and host cells in cardiometabolic diseases (Figure 2). BEV-associated PAMP and host receptor interactions in cardiometabolic disease. BEVs can interact with host cells by either directly engaging host pattern recognition receptors (PRRs) on the cell membranes like Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) or by escaping endosomal compartments to interact with cytoplasmic PRRs such as the NOD-like receptors (NLRs). These host receptors function to defend against foreign invaders, and when engaged by the pathogen-associated molecular patterns (PAMPs) present in BEVs they can trigger signaling cascades that lead to activation of inflammatory programs including NFκB and inflammasomes. Many host PRRs that play a critical role in cardiometabolic dysfunction engage PAMPs that are known to be packaged in BEVs. Thus, BEVs can serve as vehicles to deliver bacterial cargo to host cells and initiate cellular responses critical for the development of cardiometabolic pathology. Toll-like receptors (TLRs) Toll-like receptors (TLRs) are type I membrane glycoproteins that are considered to be a primary sensor of pathogens. 128 They are the most studied PRR and therefore have been most extensively linked to cardiometabolic diseases. The TLRs responsible for extracellular sensing of bacterial components are TLR1, 2, 4, 5, 6, whereas TLR7 and 9 sense bacterial components in endosomal compartments. 128 TLR4 is famously known for its recognition of extracellular bacterial lipopolysaccharide (LPS). LPS, also known as endotoxin, is thought to be a major contributor to cardiometabolic disease by priming inflammation. The term “metabolic endotoxemia” is commonly used to describe the presence of LPS in serum of patients with a variety of cardiometabolic diseases including obesity, 131 T2D, 132 and CVD. 131 , 133-135 LPS is also a well-known cargo packaged into BEVs by gram-negative bacteria. 10 , 11 While metabolic endotoxemia is often attributed to “soluble” LPS in serum, standard serum preps do not remove BEVs from the sample; therefore, LPS bound to BEVs may be an overlooked contributor to metabolic endotoxemia. Furthermore, BEV-associated LPS has been shown to elicit a stronger proinflammatory response than free LPS. 136 TLR2 is another host PRR known to be activated by BEVs. 137 , 138 This receptor, in combination with TLR1 or TLR6, recognizes lipoproteins and other bacterial cell wall components like peptidoglycan, lipoteichoic acid (LTA), and outer membrane protein A (OmpA) which are all known to be packaged in BEVs from gut microbiota. 10 , 11 , 139 Both peptidoglycan and LTA have been shown to influence cardiomyocyte function through their interaction with TLR2 which induces local inflammation and impaired cardiomyocyte contractility. 140 , 141 Signaling via TLR2 is also critical for the progression of several other cardiometabolic pathologies including foam cell accumulation in atherosclerosis, 142 heart failure, 143 obesity, hepatic steatosis, and insulin resistance. 144-146 TLR 5, well-known for its recognition of bacterial flagellin components, also has many connections to cardiometabolic diseases. BEVs are known to contain flagellar proteins and thus may also participate in the activation of host TLR5. 147 , 148 TLR5 was found to be enriched in atherosclerotic plaques, and its activation in immune cells was shown to promote macrophage recruitment and T cell responses that contribute to atherosclerosis. 149 Depletion of TLR5 was protective in multiple mouse models of atherosclerosis; 149 however, depletion of TLR5 has also been linked to the progression of other cardiometabolic pathologies including hyperlipidemia, hypertension, insulin resistance, and obesity. 150 These studies emphasize that the result of PRR signaling can depend on the context in which the signal was received, and this can lead to different outcomes depending on factors within the local tissue environment. TLR9 is one of the endosomal TLRs that recognizes unmethylated “CpG” segments which are common in bacterial DNA but not eukaryotic. 151 Many studies have described the association of bacterial DNA with BEVs, which can be packaged internally or embedded directly in the membrane. 152 TLR9 signaling is involved in regulating adipose tissue inflammation and controlling obesity related metabolic disorders. 153-155 TLR9 overactivation is also thought to be a major driver of inflammation associated with liver diseases like NAFLD and NASH. 156 C-type lectin receptors (CLRs) C-type lectin receptors (CLRs) are another class of membrane-associated host PRRs which specialize in the recognition of sugar residues (i.e. glycans). Bacterial cell walls from both gram-positive and gram-negative bacteria are decorated with glycans, which are incorporated in capsular polysaccharides, LPS, peptidoglycan, glycolipids, and flagella. 157 As previously discussed, these membrane cargoes are readily packaged into BEVs. In addition to activating inflammatory mechanisms through TLRs, these BEV cargoes may signal through CLRs to shape innate and adaptive immune responses. While these receptors play a key role in innate host defense against pathogens, the direct role of CLRs in cardiometabolic diseases is yet to be established. Aside from the proinflammatory signaling, these receptors also play an important role in phagocytic processes by host immune cells, 158 and thus their interaction with BEVs may facilitate BEV uptake by tissue-resident phagocytic cells. Nucleotide-binding oligomerization domain-like receptors (NLRs) The membrane-associated TLRs and CLRs sense extracellular and endosomal PAMPs prior to invasion. However, in the context of bacterial infection, some bacteria, or their components, can evade front-line defenses of the host cell and escape endosomal compartments into the cytoplasm. This is where Nucleotide-binding oligomerization domain-like receptors (NLRs) play a role in PAMP detection. NLRs are a diverse class of cytosolic PRRs that sense intracellular PAMPs. Two NLRs, NOD1 and NOD2, recognize intracellular fragments of peptidoglycan. 159 Multiple studies have identified BEVs as key vehicles facilitating the delivery of peptidoglycan to intracellular NOD1 receptors in host cells. 160-162 Unsurprisingly, these receptors also have strong links to cardiometabolic diseases. For instance, NOD1 is a critical mediator of glucose intolerance and diabetes associated with a high-fat diet. 163 Additionally, NOD1-deficient mice are less susceptible to developing atherosclerosis, suggesting a role for this receptor in atherosclerotic plaque formation. 164 Interestingly, BEVs can also mediate the cytosolic localization of other PAMPs suggesting that BEVs may serve as a Trojan horse allowing bacterial virulence factors to infiltrate host cells. 165 , 166 This can lead to NLR-mediated inflammasome activation. For instance, BEV-mediated delivery of flagellin from Salmonella typhimurium triggers host NLRC4 inflammasome signaling, while non-flagellated BEVs from E. coli triggered NLRP3 inflammasome. 166 Also, cytosolic delivery of LPS by BEVs led to activation of the NLRP3 inflammasome. 165 NLRP3 inflammasome activation has been described in several cardiometabolic diseases including atherosclerosis, myocardial infarction, heart failure, obesity, T2D, and NAFLD. 131 , 167 Dissemination of BEVs from the gut to cardiometabolic tissues Gut barrier disruption in cardiometabolic diseases An intact gut barrier is essential for host health, and its disruption is broadly associated with cardiometabolic diseases. 168-171 The integrity of the gut barrier is maintained by tight junction proteins including zonula occludens (ZO proteins), claudins, occludins, and zonulins, as well as a balance between intestinal epithelial cell death and regeneration. 172 Gut microbiota dysbiosis, a common feature of cardiometabolic diseases, suppresses the expression of tight-junction proteins, leading to increased intestinal permeability and presence of PAMPs in the blood. 173 The translocation of bacterial PAMPs and dissemination to cardiometabolic target tissues can result in local and systemic inflammation that contributes to metabolic dysfunction. In patients with T2D, increased gut barrier permeability is associated with increased microbial metabolites in the blood 174 and systemic inflammation. 175 Cohort analysis revealed associations between serum, urine, and fecal EVs in T2D patients, indicating systemic circulation of BEVs across bodily fluids. 176 Intestinal barrier disruption has also been reported in various cardiovascular diseases indicated by reduced expression of tight-junction proteins 82 , 177 , 178 and increased permeability to FITC-Dextran. 85 , 178-180 BEVs in gut barrier disruption BEVs are poised to traverse the gut barrier and disseminate when its integrity is weakened. However, BEVs are not just passive bystanders that take advantage of increased intestinal permeability. In fact, BEVs can also directly influence gut barrier integrity. For example, BEVs from pathogenic Campylobacter jejuni mediate cleavage of the intestinal epithelial cell adhesion protein, E-cadherin, and the tight-junction protein occludin leading to increased permeability. 181 BEVs can also compromise the intestinal barrier by promoting epithelial cell death. 182 Finally, BEVs from B. thetaiotaomicron utilize sulfatases to penetrate mucus, leading to their accumulation in subepithelial macrophages and intestinal inflammation. 183 Conversely, BEVs from A. muciniphila enhance expression of tight junction proteins, resulting in fortification of the gut barrier. 12 Given the associations of A. muciniphila with protection from cardiometabolic disease previously discussed, this study suggests that certain BEVs may also benefit cardiometabolic function. In summary, BEVs both contribute to and take advantage of gut barrier disruption which is a common feature of cardiometabolic diseases. Once BEVs bypass barrier defenses they can disseminate systemically and accumulate in cardiometabolic organs where they can influence immune response and metabolic function. Distribution of BEVs to cardiometabolic tissues After crossing the intestinal epithelium, gut-derived BEVs enter the subepithelial space, a compartment rich in immune cells, lymphatic vessels, and capillaries. At this interface, BEVs can trigger local immune activation by interacting with resident macrophages and dendritic cells. Importantly, they can also access systemic circulation through draining lymphatics or directly via capillary beds, though the route of systemic entry remains unresolved. Once in circulation, however, accumulating evidence suggests that BEVs display tissue tropism, preferentially localizing to several organs (discussed below). Whole-body fluorescent imaging studies of labeled commensal BEVs have shown their persistence in circulation and accumulation in organs such as the spleen, lungs, and liver following intraperitoneal injection. 11 , 184 However, because intraperitoneal delivery is not a typical physiological route of dissemination, these findings may not accurately reflect natural BEV biodistribution. More relevant oral administration experiments demonstrated that Bacteroides thetaiotaomicron–derived BEVs accumulated predominantly in the liver, with lower levels detected in the heart. 17 However, a limitation of fluorescence-based imaging is tissue autofluorescence, which can obscure signals and lead to underestimation of BEV accumulation, particularly in organs where BEV burden is low. Despite these technical challenges, the collective evidence indicates that gut-derived BEVs can disseminate beyond the intestine and persist in systemic tissues. Complementary approaches using immunohistochemistry have provided higher resolution of labeled BEVs within tissue sections. A series of studies by Dr. Wei Ying's group demonstrated that gut-derived BEVs accumulate in pancreatic islets, adrenal glands, and the liver of obese mice, where their presence was linked to inflammation and metabolic dysfunction. 14-16 , 185 More recently, the same group showed BEV accumulation in cardiomyocytes of aged mice, implicating them in age-related cardiac decline. 13 Together, these findings highlight the capacity of gut-derived BEVs to reach multiple metabolic and endocrine organs. They also suggest that BEV distribution may be shaped by host conditions such as obesity and aging, thereby linking gut dysbiosis to cardiometabolic comorbidities. Potential mechanisms of BEV tissue targeting Why BEVs accumulate in specific tissues remains a major unanswered question in the field. Addressing this gap will not only clarify the role of BEVs in CMDs but could also open the door for new avenues of tissue-specific therapies. Factors that are likely to shape BEV tropism include the molecular composition of their surface and the complementary receptor landscape of host tissues. BEV surfaces are enriched with diverse PAMPs that interact with host pattern recognition receptors (PRRs), but they can also carry adhesion molecules such as sialic acid adhesin (SabA), outer inflammatory protein A (OipA), neutrophil-activating protein (HP-NAP), and adhesion lipoprotein (AlpA), all of which facilitate binding to host cells. 186 Selective packaging of such molecules may direct BEVs toward particular cell types or organs. On the host side, receptor expression patterns vary widely across tissues. PRRs and other adhesion-related receptors (e.g. scavenger receptors, cell adhesion molecules) are particularly abundant on phagocytic immune cells such as macrophages and dendritic cells. Tissue-resident macrophages are found in nearly every organ, including microglia in the brain, alveolar macrophages in the lungs, red pulp macrophages in the spleen, Langerhans cells in the skin, and Kupffer cells in the liver. Each resident macrophage can be differentiated from the others based on the expression of specific surface markers. For example, Kupffer cells are characterized by their expression of CLEC4F, which is a C-type lectin important for the recognition and clearance of pathogens. 187 , 188 These cells make up the largest pool of tissue macrophages in the human body, accounting for 80–90% of total tissue macrophages. 189 Their abundance, along with high expression of relevant recognition receptors, may explain why the liver is a consistent site of BEV accumulation. 11 , 17 , 184 Additionally, nonphagocytic cells, like endothelial cells, cardiomyocytes, and fibroblasts can also attract the accumulation of BEVs through receptor expression. For example, TLR2 and 4 are upregulated in atherosclerotic plaques 190 and contributes to disease progression. 133 Additionally, these TLRs are highly expressed in the heart. 131 Finally, tissue tropism may be influenced by vascular barrier integrity. In conditions such as stroke or cerebral small vessel disease, disruption of the endothelial barrier could permit BEV entry into normally protected tissues. Whether BEV accumulation is initiated by pre-existing barrier dysfunction or results from BEV-induced local inflammation, it is ultimately the interactions between BEV cargo and host receptors that determine where BEVs persist and exert their effects in cardiometabolic tissues. The overlooked contribution of BEVs and their advantages as vehicles of dissemination Over recent decades, an emerging link between circulating bacterial products like endotoxins or DNA and cardiometabolic disease has been established. 132 , 134 , 135 , 191 However, these studies largely investigate standard serum preparations which contain both soluble products from the bacterial secretome as well as BEVs, making it impossible to differentiate the specific contributions of either fraction to CMD pathology. The separation of BEVs from soluble serum fractions requires specialized techniques including ultracentrifugation (120,000 × g) and size-exclusion chromatography. Without implementing these techniques, the context by which these bacterial products are circulating and interacting with the host is lost which can have significant mechanistic and therapeutic consequences. For this reason, hard evidence on the absolute contribution made by BEVs versus simply bacterial secretomes in host‒pathogen interactions is currently lacking. There is certainly no doubt that both are of great physiological and pathological significance. Nevertheless, there are cases where BEV can confer advantages as specialized mediators of host‒pathogen crosstalk. For example, i) it will be of great interest as this area of research expands to compare and contrast the cargo composition of BEV versus the secretome of the same bacterial species. Interestingly, one study using Staphylococcus aureus showed that whilst the compositions of the secretome and BEV cargo were highly similar, there were 54 proteins specifically packaged in BEVs. 192 This introduces the concept that BEV can carry specialized cargo that is not found in the secretome. ii) gut barrier epithelial permeability is an important regulator of bacterial-derived factors ability to impact host physiology. Conceivably, BEV can overcome a tight epithelial barrier by moving via transcytosis. 193 iii) unlike free secreted proteins, molecules encapsulated in BEVs are protected from proteases and the host immune system, thus enabling them to mediate effects upon reaching recipient cells. This is relevant for proteins and perhaps most importantly nucleic acid messengers. 194 iv) BEVs can deliver a high concentration of cargo including virulence factors. 25 , 195-197 From a classic pharmacological perspective, this may allow BEVs to stimulate a signal in recipient cells that reaches an effect threshold that is not seen with the same ligand delivered as a secreted protein at lower concentration. v) targeted delivery of cargo to specific recipient cells may be possible via BEV surface markers that allow them to interact with specific host cells. 198 In the context of cardiometabolic diseases, this means BEVs have the potential to sustain low-grade systemic inflammation, modulate metabolic signaling in distant organs, and bypass regulatory checkpoints that normally limit PAMP activity. These properties not only make BEVs powerful effectors of host physiology but also underscore the need to distinguish their contributions from those of soluble microbial products when studying microbe–host interactions in disease. The following section highlights emerging studies that move beyond indirect associations to directly demonstrate how BEVs alter immune and metabolic function in cardiometabolic disease models. Direct evidence of BEVs modulating host immunometabolism in cardiometabolic diseases We have mainly discussed indirect evidence connecting gut-derived BEVs with cardiometabolic disease. On one side, there is the body of evidence supporting the critical role of host PRRs in driving cardiometabolic dysfunction. On the other side, there is a vast body of evidence supporting the idea that gut microbiota dysbiosis and the presence of systemic bacterial PAMPs are also major contributors to cardiometabolic disease progression. We have made the logical argument that BEVs can mediate the delivery of PAMPs and contribute to metabolic dysfunction based on the idea that BEVs are known to contain inflammatory cargoes and accumulate in cardiometabolic tissues. However, a limited but growing number of studies are beginning to make the direct connection between BEVs and various cardiometabolic diseases (Table 1 and Figure 3). Table 1.Overview of the mechanistic evidence that BEVs contribute to cardiometabolic pathology.CMD contextIn vitroIn vivoHumanObesity, insulin resistance, T2DBEVs from obese mice impair insulin signaling and glucose tolerance in skeletal muscle cells in vitro. 199 BEVs from P. panacis directly inhibit insulin signaling and glucose uptake in skeletal muscle cells in vitro. 199 BEVs from diet-induced obese mice are enriched with LPS, and accumulate in the liver where they lead to inflammatory responses. 200 Oral administration of P. panacis-derived EVs induced insulin resistance and impaired glucose tolerance in recipient mice. 199 BEVs accumulate in the liver of diet-induced obese mice and impair glucose tolerance due to loss of CRIg+ macrophages. 14 BEVs accumulate in pancreatic β-cells of mice on a high-fat diet due to loss of Vsig4+ macrophages. This led to increased islet inflammation which impairs insulin production. 16 BEVs from A. muciniphila improve glucose tolerance in mice with T2D by increasing intestinal tight-junction proteins. 12 Plasma BEVs are enriched with bacterial DNA in people with obesity. 14 CRIg+ macrophages are depleted in livers of people with obesity. 14 BEVs accumulate in pancreatic β-cells of patients with T2D. 16 Vsig4+ magrophages are depleted in pancreas of patients with T2D. 16 BEVs from A. muciniphila are depleted in patients with T2D. 12 Cardiovascular diseasePrimary cardiomyocytes from young mice displayed increased inflammatory responses and reduced contractility when exposed to gut BEVs in vitro. 13 BEVs accumulate in adrenal glands of obese mice and promote adrenal inflammation, NE secretion, and hypertension due to a loss of CRIg+ macrophages. 185 BEVs infiltrate cardiomyocytes in aged mice leading to cardiac inflammation and reduced function due to a loss of Vsig4+ macrophages. 13 Transferring BEVs from aged to young mice led to impaired cardiac function in recipients. 13 Depletion of BEV associated DNA prevented pathogenic cardiovascular effects. 13 , 185 BEVs from hypertensive SHRSP rats induce blood pressure elevation in WKY rats. 201 Bacterial DNA accumulates in cardiomyocytes of aging humans. 13 Vsig4+ macrophages are depleted in heart from aging humans. 13 Liver diseaseFecal BEVs from humans with liver disease promoted inflammation and permeability of both epithelial and endothelial cells in vitro. 202 Fecal BEVs from humans with NASH activate hepatic stellate cells in vitro leading to increased cytokine production. 202 Oral administration of BEVs from human donors with NASH promoted intestinal permeability and liver fibrosis in wild type mice. 202 BEVs accumulate in liver hepatocytes and stellate cells in mice with NASH which is linked to a loss of Vsig4+ macrophages, hepatocyte inflammation, and liver fibrosis. 15 Patients with liver disease had increased proportion of LPS+ BEVs compared to healthy controls. 202 BEVs accumulate in liver hepatocytes and stellate cells in humans with NAFLD/NASH. 15 Evidence is broken down by CMD context and experimental model setting (in vitro, in vivo, or human). Overview of the mechanistic evidence that BEVs contribute to cardiometabolic pathology. Evidence is broken down by CMD context and experimental model setting (in vitro, in vivo, or human). Target organs for BEV accumulation and effects on host health. BEVs from dysbiotic microbiota at mucosal surfaces such as the gut disseminate to cardiometabolic tissues and induce inflammatory responses that lead to metabolic dysfunction. BEVs have been shown to induce inflammation and dysfunction in a variety of cardiometabolic organs including the heart, liver, adrenal glands, blood vessels, pancreas, intestines, and skeletal muscle. The cardiometabolic outcomes are shaped by the target organ of BEV accumulation and composition of BEV-associated cargo. BEVs have been increasingly linked to several cardiovascular diseases, obesity, diabetes, and metabolic liver diseases, thus serving an underappreciated role in the underlying pathophysiology of cardiometabolic diseases. Obesity, insulin resistance, and T2D Obesity is a major underlying factor contributing to many cardiometabolic diseases, most notably T2D. Along with general gut microbiota dysbiosis, obesity is also associated with changes in BEV profiles. One study found that while the total concentration of BEVs in feces were reduced by diet-induced obesity, the proportion of LPS + BEVs was markedly increased. These LPS + BEVs accumulated in the liver, where host TLR4 expression was high and led to the upregulation of inflammatory responses. 200 Another study by Luo et al. also found that BEVs accumulate in the liver of diet-induced obese mice. 14 This study attributed this accumulation to the loss of a bacterial-clearing population of resident macrophages (Kupffer cells) which express the complement receptor CRIg, a population that is also depleted in humans with obesity. 14 Furthermore, BEVs from obese mice were shown to impair glucose tolerance and insulin sensitivity in non-obese mice, suggesting that BEVs drive this metabolic dysfunction. 14 BEVs have also been shown to accumulate in the pancreatic β-cells in patients with obesity and T2D as well as mice on a high-fat diet but not lean controls. 16 Transfer of BEVs from obese mice to non-obese recipients led to increased pancreatic islet inflammation along with impaired glucose tolerance and insulin production. 16 This effect was attributed to the loss of a separate population of tissue-resident macrophages that express a different complement receptor, Vsig4. 16 This is further supported by evidence that BEVs from diet-induced obese mice impaired insulin signaling and glucose tolerance of skeletal muscle cells in vitro. 199 Moreover, BEVs specifically from P. panacis, which are enriched in the gut of diet-induced obese mice, directly inhibited insulin signaling pathways and glucose uptake in skeletal muscle cells compared to control BEVs. 199 Specific BEVs can also support proper cardiometabolic function. Chelakkot et al. noted that BEVs from A. muciniphila are depleted in patients with T2D, and reintroduction of these BEVs improved glucose tolerance in diet-induced T2D mice by enhancing intestinal tight-junction protein expression. 12 Cardiovascular disease BEVs have been shown to play a causal role in cardiovascular disease pathology. Cecal BEV cargo profiles are altered in the spontaneously hypertensive stroke-prone rat (SHRSP), a commonly used model of hypertension. 201 Furthermore, transplant of cecal BEVs from hypertensive SHRSP rats elevated the blood pressure of normotensive recipients, whereas transplant of BEVs from normotensive controls had no effect on recipient blood pressure. 201 This study indicates that BEVs are capable of regulating host blood pressure; however, which cargo and host tissues are driving this mechanism remains an open question. Gao et al. found that BEVs accumulated in the adrenal glands of obese mice due to a decrease of tissue-resident CRIg + macrophages. This accumulation of BEVs promoted adrenal inflammation and norepinephrine secretion which led to hypertension. 185 This group also showed that BEVs infiltrate cardiomyocytes in aging mice, leading to cardiac inflammation and reduced cardiomyocyte function. 13 Furthermore, the effects of BEVs on cardiovascular health seem to be mediated by their DNA cargo because specific depletion of bacterial DNA from BEVs blunted their pathogenic effects. 13 , 185 Liver disease Similar to the BEV profile observed in obese individuals, patients with liver disease (NAFLD and NASH) have less total BEVs in their feces compared to healthy controls, but the BEVs contain significantly more LPS. 202 In vitro, fecal BEVs from donors with liver disease promoted both epithelial (gut) and endothelial (blood vessel) inflammation and permeability, while circulating BEVs from these donors induced inflammation in hepatic stellate cells. 202 In vivo oral administration of BEVs from NASH donors increased intestinal permeability and liver fibrosis in wild-type mice. 202 Additionally, BEVs were shown to accumulate in liver hepatocytes and hepatic stellate cells of diet-induced NASH mice as well as humans with NAFLD/NASH. 15 This accumulation of BEVs was concomitant with a loss of Vsig4 + macrophages and triggered hepatocyte inflammation and liver fibrosis. 15 Translational potential of BEVs BEVs as biomarkers Due to the ubiquitous and systemic nature of their propagation, BEVs represent an attractive new category of biomarker for clinical diagnosis. BEVs have been reliably detected in saliva, stool, urine, and blood—even in healthy individuals—highlighting their accessibility for noninvasive sampling. 203 In clinical contexts, BEVs could provide earlier or more sensitive diagnostic readouts than some traditional methods. The composition, abundance, and distribution of BEVs may reflect specific disease states. In healthy individuals, the distribution of BEVs across different biological sites is typically distinct. However, the breakdown of barriers such as the gut epithelium can lead to a more homogenous distribution which can represent specific disease states. For example, Nah et al. found that BEVs from the blood, urine, and stool of patients with T2D were more similar in composition across sites than in healthy individuals. 176 This suggests that the spatial distribution of BEVs could serve as a potential diagnostic signature for some cardiometabolic diseases. Indeed, BEVs have already produced promising results as biomarkers in periodontal and gastrointestinal medicine. 204 , 205 Importantly, BEV-based biomarker discovery can leverage multiple layers of information, including their physical presence, surface antigens, and internal cargo. Integrating these features into multiplexed diagnostic platforms could enable earlier detection, improved disease stratification, and dynamic monitoring of therapeutic responses in cardiometabolic disorders. Given their inherent ability to interact with host tissues, the same properties that make BEVs attractive as biomarkers also position them as versatile platforms for therapeutic delivery. BEVs as conveyors of nutritional impact Having focused on the impact of BEV on inflammation and cardiometabolic disease it is also worthy to consider front-end inputs that shape gut flora composition and, consequently, the secreted factors from that microbiota. 206 Diet stands out as the principal environmental factor which can profoundly shape the gut microbiota. 206 , 207 Indeed, although still an emerging area of research, several recent studies have summarized the impact of high fiber, fat or protein diets on BEV profiles. A high fiber diet in pigs was found to produce BEVs enriched for protein derived from Bacilli, Clostridiales, and Enterobacteriales. 208 In response to high-protein diets in mice there was an increase in overall BEV production 209 , 210 and this observation was consistent with studies of cultured E. coli Nissle 1917 where treatment with glycine increased BEV production. 211 A strong impact of high-fat diets on microbiota composition is well established and it has now been shown that the amount, size, and composition of BEV, including elevated LPS content, are also altered. 199 Much more research is needed in this important area to resolve the effect of not only the classes of nutrients we briefly mentioned above, but also specific factors within these groups as well as a wider spectrum of diet-delivered factors. Overall, we believe it is important to remember that future studies should ensure that conclusions on a purported nutrition-bacteria-BEV-cardiometabolic axis should be based on changes in functionality rather than compositionality. Engineering BEVs for therapeutic application Beyond their potential as biomarkers, BEVs are emerging as versatile platforms for therapeutic delivery. Their nanoscale size, natural stability, ability to cross biological barriers, and inherent capacity to interact with host cells make them attractive vehicles for targeted drug and vaccine delivery. Because they originate from bacteria, BEVs have the potential to be produced with high yields and engineered to display or carry diverse bioactive molecules, including proteins, nucleic acids, and small-molecule therapeutics. The clinical feasibility of BEV-based vaccines has already been demonstrated. The BEV-based Neisseria meningitidis serogroup B vaccine Bexsero® has received FDA approval and is widely used for meningitis B prevention. 212 Similarly, a BEV-based quadrivalent Shigella vaccine has shown strong safety and immunogenicity in clinical trials. 213 , 214 Experimental BEV-based vaccines have also shown efficacy against Yersinia pestis, the causative agent of pneumonic plague, which currently has no approved vaccine. 215 In addition to vaccines, BEVs can be engineered as therapeutic delivery systems. Carvalho et al. provided a compelling proof-of-concept by modifying the commensal gut bacterium Bacteroides thetaiotaomicron to produce BEVs containing the human therapeutic protein keratinocyte growth factor-2 (KGF-2). When delivered orally, these engineered BEVs reduced intestinal inflammation in mouse models of colitis, demonstrating the feasibility of targeted delivery of therapeutics by BEVs. 216 This approach could be adapted for the delivery of anti-inflammatory agents, metabolic regulators, or other disease-modifying molecules in cardiometabolic disorders. The proverbial door was opened for using BEV-based therapeutics to treat cardiometabolic diseases when a preclinical study by Sundaram et al. showed that oral administration of BEVs from Akkermansia muciniphila reversed the insulin resistance associated with diet-induced T2D in mice. 217 Additionally, intravenous administration of BEVs from Akkermansia muciniphila increased circulating T regulatory cells and lowered blood pressure in the spontaneously hypertensive rat model. 218 Together, these studies highlight the versatility of BEVs as customizable, biocompatible delivery platforms. Leveraging their ability to interact with specific tissues and cell types could enable highly targeted interventions for cardiometabolic diseases, either by dampening harmful inflammatory signaling or by restoring protective microbial functions lost during dysbiosis. Conclusions and future perspectives Despite their initial description in 1966, 219 BEVs have been largely overlooked or mislabeled in the context of human disease, prompting our description of them as microbial “dark matter”. BEVs have recently emerged as potent mediators of microbiota–host communication, capable of influencing both local intestinal and distant tissues. This review highlights the dualistic nature of BEVs in cardiometabolic disease (CMD), where they can either exacerbate or mitigate disease progression depending on their microbial origin and cargo. BEVs carry a diverse array of bioactive molecules including PAMPs, nucleic acids, and proteins that interact with host PRRs to modulate inflammation and metabolic function. Their ability to traverse the gut barrier and accumulate in cardiometabolic tissues positions them as key contributors to CMD pathogenesis. Moreover, growing evidence supports their translational potential as biomarkers and therapeutic vectors. However, significant gaps remain in our understanding of BEV cargo composition, tissue tropism, and functional outcomes in vivo. Our understanding of the role of BEVs in host health and disease has been hindered by a number of technical challenges in studying BEVs, including the difficulty of separating them from both cellular and molecular fractions of biological samples, distinguishing host from bacterial EVs, and a lack of unbiased assessment of BEV cargo. Previous studies examining BEV production and composition have largely relied on the use of monocultured bacterial sources and selective cargo detection. Up to 94% of BEV characterization studies have sourced BEVs from bacterial cell culture methods 139 instead of complex communities like the gut microbiota. This is significant because BEV production and cargo packaging are greatly affected by environmental factors, like nutrient availability, so BEVs from cell cultures may not accurately reflect those produced by the same strain in the gut. Thus, the characterization of BEVs from healthy and diseased gut microbiota is crucial for determining the cargoes that are truly relevant to human disease. Furthermore, when BEVs from complex communities like the gut microbiota are characterized, the evaluation of cargo has been largely limited to well-known bacterial membrane components like LPS, peptidoglycan, or outer membrane proteins (Omps). A more complete characterization of BEV cargo composition in health and disease is likely to reveal new mechanisms of bacteria‒host communication that contribute to cardiometabolic disease pathology. The use of integrated multiomics approaches to profile the complete proteome, transcriptome, lipidome, and metabolomes of complex pools of BEVs from cardiometabolic disease samples will eliminate the current selective detection bias and provide more precise associations between BEV composition and disease progression. These findings should then be further investigated in animal models to establish causal relationships. For example, characterizing and cross-referencing the metagenomes of both the BEVs circulating in patients or animals with cardiometabolic disease and their respective gut microbiota could reveal the identities of the parent bacteria responsible for the pathogenic BEVs. Additionally, there is a growing awareness of how bacterial RNA can influence host gene expression, but whether BEVs mediate this process and how it manifests in cardiometabolic disease are yet to be determined. This could be addressed by evaluating transcriptomic profiles of circulating BEVs in cardiometabolic patients or animal models. Finally, single-cell and spatial-omics methods could be used to better understand the BEV-host crosstalk directly in dysfunctional tissues. Achieving a more comprehensive characterization of BEV cargo will improve our understanding of their roles in cardiometabolic diseases and reveal unknown mechanisms of BEV trafficking and organ accumulation. Further research into the origins, cargo, trafficking, and functional effects of BEVs in metabolic disorders is crucial to understanding this complex relationship and translating findings into clinical applications. Such studies hold a significant promise for developing diagnostic tools and targeted therapies to address this growing global health issue.